drugset / Trial / NCT00267683

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

NCT00267683

Phase 3 Terminated 9 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Japan. This is a clinical trial to study the efficacy and safety of thrice daily Insulin Aspart compared to Glibenclamide in type 2 diabetic patients.

Timeline

Start
2005-12
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Glyburide Small molecule
Subject insulin aspart Protein / enzyme biologic